Earnings Releases·Nov 4, 2026, 4:40 PM ET

LeMaitre Vascular, Inc. — Q3 2026 Earnings Summary

Q3 2026 sales reached $68.0 million (up 11% YoY, 12% organic), while diluted EPS declined 14% YoY to $0.65; however, adjusted EPS rose 5% YoY to $0.65, and adjusted EBITDA increased 7% YoY to $20.5 million.
Management reaffirmed full-year 2026 guidance for $274.8–$276.8 million in sales (11% growth) and $2.77–$2.82 in EPS (11% total, 18% adjusted growth), driven by biologics and international expansion.
In October, the company acquired vascular assets from B. Braun for $19.2 million, expected to contribute approximately $150,000 in Q4 sales with a break-even operating impact.
Capital return initiatives include a newly declared quarterly dividend of $0.25 per share and an authorized share repurchase program of up to $100.0 million through February 2027.
Cash and cash equivalents increased sequentially by $13.5 million to $390 million as of September 30, 2026, while headcount grew 7% to 678 employees.